Objective and design: The use of proton pump inhibitors in acid-related diseases such as peptic ulcer or erosive reflux oesophagitis is well established. The aim of the current nationwide, multicentre ...
Please provide your email address to receive an email when new articles are posted on . A 500 mg intramuscular injection of sotrovimab was noninferior to an IV infusion of the investigational ...
The benefit of reduced intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) as salvage treatment for relapsing multiple myeloma (MM) Bortezomib (Bz) is a novel proteasome ...
Rapid 30-minute isatuximab infusions improve patient experiences and reduce healthcare system burdens without compromising safety. FDA-approved isatuximab with VRd shows a 40% risk reduction in ...
Please provide your email address to receive an email when new articles are posted on . More patients in the ED with hemoptysis saw an end to the condition with nebulized vs. IV tranexamic acid.
RANIDO: A phase III clinical trial of racotumomab-alum or nimotuzumab versus docetaxel in advanced non-small cell lung cancer patients. Background: To date convincing clinical success with oncolytic ...
The phase 3 IRAKLIA trial showed isatuximab's OBDS matches IV efficacy and pharmacokinetics, with fewer injection-site reactions. Subcutaneous isatuximab demonstrated a 71.1% objective response rate, ...
The probability of spontaneous conversion to sinus rhythm (SVC) was increased with the intravenous administration of magnesium and potassium in patients with nonpermanent atrial fibrillation ...
Subcutaneous administration of Opdivo, could increase efficiency and reduce wait times for patients, as one expert explains to CURE®. Subcutaneous (SC) administration of Opdivo (nivolumab) was not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results